Emily is a former editorial intern at Spectrum and a graduate student in New York University’s Science, Health & Environmental Reporting Program. Previously, Emily worked on aging research in Boston, Massachusetts. She has a B.A. in chemistry from Williams College in Williamstown, Massachusetts.
Emily Harris
Former news intern
Spectrum
From this contributor
Prenatal exposures; Angelman trial suspension; autistic adult well-being
This month’s issue of the Null and Noteworthy newsletter breaks down some negative results involving prenatal exposures, an experimental treatment for Angelman syndrome, and the role that age at autism diagnosis plays in subsequent outcomes, and more.
Prenatal exposures; Angelman trial suspension; autistic adult well-being
Null and Noteworthy: Modified MRI; father findings
This month’s newsletter tackles null findings from an attempted replication of a “revolutionary” MRI approach and an analysis of family genetics.
Null and Noteworthy: Modified MRI; father findings
Null and Noteworthy: Reinforcing rigor; medication medley
This month’s newsletter highlights findings on the use of three medication types during pregnancy.
Null and Noteworthy: Reinforcing rigor; medication medley
Null and Noteworthy: COVID-19 conclusions; diagnosis duplication; oxytocin again
This month’s newsletter explores the pandemic’s effects on autism rates, trends in co-occurring mental health conditions, and the impact of intranasal oxytocin.
Null and Noteworthy: COVID-19 conclusions; diagnosis duplication; oxytocin again
Null and Noteworthy: Medication timing; oxytocin amounts; sensory sameness
Parents’ health, treatment dosages and sensory perception feature in this month’s crop of null and replicated results.
Null and Noteworthy: Medication timing; oxytocin amounts; sensory sameness
Explore more from The Transmitter
U.S. national primate research centers face an uncertain future
The facilities were meant to last 100 years. Four decades shy of that mark, amid flatlined funds and mounting political pressure, their directors are trying to find a path forward.
U.S. national primate research centers face an uncertain future
The facilities were meant to last 100 years. Four decades shy of that mark, amid flatlined funds and mounting political pressure, their directors are trying to find a path forward.
What if nonhuman primate research goes away?
As the U.S. government takes steps to stop using nonhuman primates in research, The Transmitter investigates what that shift could mean for neuroscience.
What if nonhuman primate research goes away?
As the U.S. government takes steps to stop using nonhuman primates in research, The Transmitter investigates what that shift could mean for neuroscience.
The neuroscience questions that need nonhuman primates
The Transmitter asked 17 neuroscientists what questions might remain unanswered if support for nonhuman primate research continues to decline.
The neuroscience questions that need nonhuman primates
The Transmitter asked 17 neuroscientists what questions might remain unanswered if support for nonhuman primate research continues to decline.